JAK2 and acquired polycythemia vera: For JAK2, JAK2V617F is the most common mutation that is implicated in Philadelphia-negative myeloproliferative neoplasms (MPNs), and this covers polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF).